CES: INDICE CHIMIO-ENDOCRINIEN BASÉ SUR PAM50 CONTRE LE CANCER DU SEIN AVEC RÉCEPTEURS HORMONAUX POSITIFS À RISQUE MOYEN DE RÉCIDIVE

摘要

The present invention refers to the development of a Chemo Endocrine Score (CES), based on the well-known PAM50 assay, for predicting whether a breast cancer patient is responsive to a chemotherapy or endocrine treatment, particularly in an HR+/HER2- breast patient beyond PAM50 Risk of Relapse (ROR) and intrinsic subtypes. Particularly, the clinical utility of this CES predictor lies in the PAM50 ROR-intermediate group, where the proportion of each CES group (endocrine-sensitive, intermediate and chemo-sensitive) is more than 25%.